Regeneron Pharmaceuticals Inc
(BSP:REGN34)
R$
89.25
1.25 (1.42%)
Market Cap: 590.31 Bil
Enterprise Value: 549.72 Bil
PE Ratio: 24.59
PB Ratio: 3.63
GF Score: 86/100 Regeneron Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Nov 15, 2023 / 02:30PM GMT
Release Date Price:
R$64.26
Akash Tewari
Jefferies LLC, Research Division - Equity Analyst
Good afternoon, everyone. I was just joking with the Regeneron team that [if] there's a biotech bear market, I don't see it in London. These are packed rooms. It's really great to see everyone. And this is -- I also think that we're going to have an XBI rally. But that's my hot take for the day. That aside, I do have the pleasure of hosting the Regeneron team, Bob Landry, CFO; and then Ryan Crowe, Head of Investor Relations.
I will hand it off to them to make some introductory remarks and then we'll get started.
Ryan Crowe
Regeneron Pharmaceuticals, Inc. - VP of IR
Thanks, Akash. Great to be here again. And this is a very crowded conference. I think it might be time for a bigger hotel.
Akash Tewari
Jefferies LLC, Research Division - Equity Analyst
The claustrophobia is a feature, not a [function].
Ryan Crowe
Regeneron Pharmaceuticals, Inc. - VP of IR
I see. Anyway, I'll do some FLS disclaimer
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot